Literature DB >> 11322480

Post-transcriptional control of c-erb B-2 overexpression in stomach cancer cells.

C D Bae1, Y S Juhnn, J B Park.   

Abstract

The growth factor receptor oncogene, c-erb B-2, is frequently overexpressed in the adenocarcinomas of breast, ovary, lung and stomach. Although the mechanism of erb B-2 overexpression is thought as the result of transcriptional upregulation in many primary human carcinomas, expression rate of c-erb B-2 at mRNA level is usually lower than the level of translated protein. We also found that the expression of erb B-2 in SNU-1 stomach cancer cells was greater at post-transcription level (Bae et al., 1993). To explore the underlying mechanism of erb B-2 protein overexpression, we have chosen two cells lines, SNU-1 and SNU-16 where transcription rate of erb B-2 was closely resemble to each other while expressed protein levels were quite different. The synthesis rate of erb B-2 protein in SNU-1 cells was faster than SNU-16 cells while levels of erb B-2 mRNA were found to be similar in both cell lines. The half-life of the expressed erb B-2 protein was not significantly different in both cell lines. Analysis of the 5' untranslated region (UTR) of erb B-2 mRNA (-1approximately-323) showed no sequence abnormality in both cell lines. However, ribonuclease protection assay using cloned 5 UTR sequence revealed that the size of 5' UTR of erb B-2 mRNA which associate with transcription initiation site(s) in SNU-1 cells was longer than that in SNU-16. These results suggest that the increased erb B-2 protein synthesis rate possibly due to the redundant selection of transcription initiation might be a mechanism of erb B-2 overexpression in SNU-1 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322480     DOI: 10.1038/emm.2001.3

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  6 in total

1.  MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Authors:  L Venturutti; R I Cordo Russo; M A Rivas; M F Mercogliano; F Izzo; R H Oakley; M G Pereyra; M De Martino; C J Proietti; P Yankilevich; J C Roa; P Guzmán; E Cortese; D H Allemand; T H Huang; E H Charreau; J A Cidlowski; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

2.  Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer.

Authors:  Hong Suk Song; Young Rok Do; In Ho Kim; Soo Sang Sohn; Kun Young Kwon
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

3.  Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells.

Authors:  Anuradha Mehta; Christopher R Trotta; Stuart W Peltz
Journal:  Genes Dev       Date:  2006-04-05       Impact factor: 11.361

4.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

5.  Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.

Authors:  Fei Zhou; Ning Li; Weihua Jiang; Zhaolai Hua; Lin Xia; Qingyi Wei; Liwei Wang
Journal:  World J Surg Oncol       Date:  2012-12-18       Impact factor: 2.754

6.  HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.

Authors:  Z Latif; A D Watters; I Dunn; K M Grigor; M A Underwood; J M S Bartlett
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.